Indian pharmaceutical company grants Abbvie authorization for new blood cancer drug

阿斯達克財經網
2025.07.10 16:11

美國生物製藥公司 AbbVie(ABBV.US) 與印度藥企 Glenmark Pharmaceuticals 旗下創新研發部門簽訂授權協議，Glenmark 將其研發中針對多發性骨髓瘤 (multiple myeloma) 的創新藥物授權予 Abbvie，首期將獲支付 7 億美元。

Glenmark 董事總經理 Glenn Saldanha 透露，公司有機會按研發、監管及商業化進展再獲最多 12.3 億美元的里程碑款項。藥物若日後成功推出市場，Glenmark 亦將獲得基於淨銷售額的分級兩位數特許權使用費。

Source: 阿斯達克財經網 The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.